GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, is set to present at the Emerging Growth Conference on July 16, 2025. The presentation will feature Chairman and CEO David Dodd discussing the company's pipeline, including the GEO-MVA vaccine for Mpox/smallpox, the GEO-CM04S1 COVID-19 vaccine, and Gedeptin®, a therapy for solid tumors. The event offers a platform for shareholders and the investment community to engage directly with the company's leadership.
The GEO-MVA vaccine, designed for global preparedness against Mpox and smallpox, has recently received favorable feedback from the European Medicines Agency. Meanwhile, the GEO-CM04S1 vaccine is undergoing Phase 2 trials to assess its efficacy in immunocompromised individuals and as a booster for healthy adults. Gedeptin® is advancing towards a Phase 2 trial for head and neck cancer, showcasing GeoVax's commitment to addressing unmet medical needs.
GeoVax's presentation will also emphasize the role of its MVA platform and U.S.-based manufacturing in enhancing vaccine supply diversification and pandemic readiness. The conference represents a significant opportunity for stakeholders to gain insights into GeoVax's strategic direction and the potential impact of its programs on public health and biosecurity.
Interested parties can register for the conference here, with a replay available post-event on the Emerging Growth website and YouTube channel. This engagement underscores GeoVax's dedication to transparency and innovation in the biotechnology sector.
